Defeating lung cancer

By Rob Clancy, staff writer. Reviewed by Associate Professor Daniel Gough

 Associate Professor Dan Gough researching defeating lung cancer
Associate Professor Dan Gough

Motivation is not hard to come by in Associate Professor Dan Gough’s line of work – he is reminded every time he’s asked what he does for a living.

“When I tell them that I am a cancer researcher it inevitably leads to a conversation about how they have been touched by cancer and how important the work is,” A/Prof Gough stated.

The disease A/Prof Gough is working to defeat is the most lethal cancer worldwide: lung cancer.

Immunotherapy: empowering the immune system

With his team in Hudson Institute’s Centre for Cancer Research, he has developed sophisticated models of lung cancer which allow them to model disease progression and observe response to current treatments in patients. These models can allow the team to test new drugs that will

Lung cancer facts

  • Every minute, one Australian dies from lung cancer
  • Lung cancer is the most lethal cancer worldwide
  • 1 in 10 men with lung cancer have no smoking history
  • 1 in 3 women with lung cancer have no smoking history
  • Be effective treatments on their own
  • Improve the response to current care
  • Reduce metastatic spread.
  • Uniting fundamental science and technology.

A major focus is to improve on a new class of immunotherapy drugs which empower the patient’s own immune system to kill their tumour.

Insights into tumour formation

But sometimes it’s the nuts and bolts of cancer development and growth that can have the most impact.
“I have spent 20 years building better model systems and knowledge about tumour formation,” A/Prof Gough said.

“Scientists now have access to new technologies which, when combined with these models, enable the team to ask critical questions about tumour interaction with the other cells in the tissue that it is forming in.”

Uniting fundamental science and technology

Interaction between STAT3 and SLIRP blue dye shows the cell nucleus
Interaction between STAT3 and SLIRP blue dye shows the cell nucleus

A/Prof Gough’s work was recognised on several fronts throughout 2023, from fundamental discovery research into how tumour cells change the way they generate the energy required for growth (Cell Reports) to large drug-screening studies in lung cancer in the Journal of Experimental and Clinical Cancer Research (JECCR) and paediatric cancers (Cancer Cell).

Breakthroughs in chemotherapy resistance

The publication in JECCR identified why lung cancer stops responding to the most commonly used frontline chemotherapy – platinum. Importantly, the team identified a drug that restored platinum sensitivity, ultimately doubling the lifespan in a preclinical lung cancer model.

It is this type of fundamental research – that so often goes unnoticed – which identifies potential targets for cancer treatment and ultimately forms the basis of the next wave of cancer treatments.

“These insights will be critical to refining the new generation of cancer treatments.”

Future directions: leveraging models and technologies

The next step for Hudson Institute’s lung cancer specialists is to leverage the preclinical models they have developed and embrace new technologies to understand how to achieve better outcomes for lung cancer patients.

The future is full of exciting possibilities in this field and as A/Prof Gough knows, all the motivation he needs is never far away.

“Applying our understanding of fundamental biological systems to the complex setting of tumour growth is essential to identify new treatments,” said A/Prof Gough.

Collaborators | Garvan Institute; Monash Biomedicine Discovery Institute; Monash Institute of Pharmaceutical Sciences; Western Sydney University; CNRS (France); New York University (USA); University of Toronto (Canada)

This research was supported by | Peninsula and South East Oncology; Victorian Cancer Agency

Journal | Cell Reports

Title | A STAT3 protein complex required for mitochondrial mRNA stability and cancer.

View publication |

Journal | Journal of Experimental and Clinical Cancer Research

Title | MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat

View publication |

About Hudson Institute

Hudson Institute’ s research programs deliver in five areas of medical need – inflammation, cancer, reproductive health, newborn health, and hormones and health. More

Hudson News

Get the inside view on discoveries and patient stories

“Thank you Hudson Institute researchers. Your work brings such hope to all women with ovarian cancer knowing that potentially women in the future won't have to go through what we have!”

Alana Chantry